Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

Liraglutide, also owned by Novo Nordisk®, is the world's 3 rd most popular glucagon-like peptide-1 ("GLP-1") or glucose-dependent insulinotropic ("GIP") weight loss/diabetes drug on the market today.

The firm attributes its lower revenue projections to conservative estimates for Levemir and Victoza, two of Novo Nordisk's products. With an impressive gross profit margin of 84.66% and a P/E ...